Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
Mod Pathol. 2010 Oct;23(10):1325-33. doi: 10.1038/modpathol.2010.120. Epub 2010 Jun 18.
TMPRSS2-ERG gene rearrangement is seen in about half of clinically localized prostate cancers, yet controversy exists with regard to its prognostic implications. Similarly, the relationship of TMPRSS2-ERG fusion to Gleason score and morphology remains uncertain. We assigned Gleason scores and recorded morphological features for 521 clinically localized prostate cancers sampled in triplicate and arrayed in eight tissue microarray blocks. Fluorescence in situ hybridization was performed to delineate TMPRSS2-ERG aberrations. Using maximum Gleason score, based on three core evaluation, and overall Gleason score, based on prostatectomy sections, Fisher's exact test was performed for tumors with TMPRSS2-ERG translocation/deletion, copy number increase (≥ 3) of the TMPRSS2-ERG region without translocation/deletion, and copy number increase and concomitant translocation/deletion. In all, 217 (42%) translocation/deletion and 30 (5.9%) copy number increase-alone cases were detected. Among 217 translocation/deletion cases, 32 had translocation/deletion with copy number increase. In all, 237, 200, and 75 cancers had maximum core-specific Gleason score of 6, 7, and 8-10, respectively. Tumors with translocation/deletion tended toward lower Gleason scores than those without (P=0.002) with similar results for overall Gleason score (P=0.02); copy number increase cases tended toward higher Gleason scores than those without (P<0.001). Gleason score of 8-10 tumors demonstrated lower odds of translocation/deletion (odds ratio (OR) 0.38; 95% CI 0.21-0.68) and higher odds of copy number increase alone (OR 7.33; 95% CI 2.65-20.31) or copy number increase+translocation/deletion (OR 3.03; 95% CI 1.12-8.15) relative to Gleason score of <7 tumors. No significant difference in TMPRSS2-ERG incidence was observed between patients with and without cribriform glands, glomerulations, signet-ring cells, or intraductal cancer (P=0.821, 0.095, 0.132, 0.375). TMPRSS2-ERG gene fusion is associated with lower core-specific and overall Gleason scores and not with high-grade morphologies. Conversely, TMPRSS2-ERG copy number increase, with or without rearrangement, is associated with higher Gleason score. These findings indicate that translocation/deletion of TMPRSS2-ERG is not associated with histological features of aggressive prostate cancer.
TMPRSS2-ERG 基因重排约见于半数临床局限性前列腺癌,但关于其预后意义仍存在争议。同样,TMPRSS2-ERG 融合与 Gleason 评分和形态的关系也不确定。我们对 521 例临床局限性前列腺癌进行了三次重复采样,并排列在 8 个组织微阵列块中,为其分配 Gleason 评分并记录形态特征。采用荧光原位杂交技术描绘 TMPRSS2-ERG 异常。基于三次核心评估的最大 Gleason 评分和基于前列腺切除术切片的总 Gleason 评分,采用 Fisher 精确检验,比较 TMPRSS2-ERG 易位/缺失、TMPRSS2-ERG 区无易位/缺失但拷贝数增加(≥3)和拷贝数增加且同时易位/缺失的肿瘤。共检出 217 例(42%)易位/缺失和 30 例(5.9%)拷贝数增加但无易位/缺失的病例。在 217 例易位/缺失病例中,32 例存在易位/缺失伴拷贝数增加。237、200 和 75 例肿瘤的最大核心特异性 Gleason 评分分别为 6、7 和 8-10。与无易位/缺失的肿瘤相比,易位/缺失的肿瘤倾向于较低的 Gleason 评分(P=0.002),总 Gleason 评分也有类似结果(P=0.02);拷贝数增加的病例倾向于较高的 Gleason 评分(P<0.001)。Gleason 评分为 8-10 的肿瘤易位/缺失的可能性较小(比值比(OR)0.38;95%置信区间(CI)0.21-0.68),且拷贝数增加单独存在(OR 7.33;95% CI 2.65-20.31)或拷贝数增加伴易位/缺失(OR 3.03;95% CI 1.12-8.15)的可能性较大,与 Gleason 评分<7 的肿瘤相比。易位/缺失与有或无筛状腺体、肾小球、印戒细胞或导管内癌的患者之间,TMPRSS2-ERG 的发生率无显著差异(P=0.821、0.095、0.132、0.375)。TMPRSS2-ERG 基因融合与较低的核心特异性和总 Gleason 评分相关,而与高级别形态无关。相反,TMPRSS2-ERG 拷贝数增加,无论是否有重排,都与较高的 Gleason 评分相关。这些发现表明,TMPRSS2-ERG 的易位/缺失与侵袭性前列腺癌的组织学特征无关。